Performance of (89)Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

PURPOSE: Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of (89)Zirconium ((89)Zr)-mAb is a potential imaging biomarker for tumor targeting, since it de...

Descripción completa

Detalles Bibliográficos
Autores principales: Jauw, Yvonne W. S., Zijlstra, Josée M., de Jong, Daphne, Vugts, Danielle J., Zweegman, Sonja, Hoekstra, Otto S., van Dongen, Guus A. M. S., Huisman, Marc C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5218417/
https://www.ncbi.nlm.nih.gov/pubmed/28060891
http://dx.doi.org/10.1371/journal.pone.0169828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5218417/
https://www.ncbi.nlm.nih.gov/pubmed/28060891
http://dx.doi.org/10.1371/journal.pone.0169828

Ejemplares similares